Bryostatin-1 in Treating Patients With Recurrent Non-Hodgkin's Lymphoma

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Phase II trial to study the effectiveness of bryostatin-1 in treating patients with recurrent non-Hodgkin's lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Cancer Institute (NCI)
• Treatments: Bryostatin 1

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed non-Hodgkin's lymphoma

• Working formulation low-, intermediate-, and high-grade histologies eligible

• Mantle cell and marginal zone lymphoma eligible

• Relapse after at least 1 doxorubicin-containing regimen required

• No more than 2 prior chemotherapy regimens

• One prior biologic therapy in addition to the 2 prior chemotherapy regimens allowed

• No prior bone marrow transplantation

• Ineligible for treatment on higher priority protocols

• Patients eligible for bone marrow transplantation may be treated to reduce tumor bulk

• Bidimensionally measurable disease required

• No history of primary or metastatic CNS disease

PATIENT CHARACTERISTICS:

• Age: Any age

• Performance status: Zubrod 0-2

• Life expectancy: Greater than 12 weeks

• Absolute neutrophil count at least 1,000/mm3

• Platelet count at least 100,000/mm3

• Bilirubin no greater than 1.8 mg/dL

• Transaminases no greater than 2.5 times normal

• Creatinine no greater than 1.5 mg/dL OR creatinine clearance greater than 70 mL/min

• No HIV antibody

• No serious intercurrent illness

• No pregnant or nursing women

• Effective contraception required of fertile patients throughout study and for 1 year thereafter

PRIOR CONCURRENT THERAPY:

-At least 4 weeks since prior therapy (6 weeks since mitomycin) and recovered